Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: Tumor growth assessment: data for each time-point in mm 3 are mean ± SEM. ( A ) M-234p, N = 6/group; Day 21: Control (600.96 ± 93) vs Cy+Los (20.96 ± 9.01) ( P < 0.05); ( B ) M-406, N = 6–7/group; Day 17: Control (1397.00 ± 328.32) vs Cy (372.00 ± 55.25) ( P < 0.01), vs Los (451.07 ± 143.94) ( P < 0.05), vs Cy+Los (123.43 ± 45.71) ( P < 0.001). Kruskal-Wallis multiple comparison test and Dunn’s post-test. Overall survival (Kaplan-Meier), Median Survival (MS): ( C ) M-234p, N = 5–6/group; Control (MS: 34 days); Cy (MS: 47 days); Los (MS: 32 days); Cy+Los (MS: undefined, Day 32: 60% [3/5] complete tumor regressions). Cy+Los vs Control, vs Los, vs Cy ( P < 0.01); ( D ) M-406, N = 6–7/group); Control (MS: 24 days); Cy (MS: 36.5 days); Los (MS: 33 days); Cy+Los (MS: 47 days). Control vs Cy ( P < 0.01), vs Los ( P < 0.01), vs Cy+Los ( P < 0.001); Cy+Los vs Cy ( P < 0.05), vs Los ( P < 0,001). Log-rank Test.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: Proliferation: Ki67 + cells/field (median, range). ( A ) M-234p Control vs Cy+Los ( P < 0.01); ( B ) M-406 Control vs Cy+Los ( P < 0.05; ( C ) M-234p and ( D ) M-406, representative images of Control and Cy+Los treated tumors, 1000× magnification. Apoptosis: TUNEL + cells/field (median, range). ( E ) M-234p Control vs Cy+Los ( P < 0.05): ( F ) M-406 N. S; Kruskal-Wallis multiple comparison test and Dunn’s post-test; ( G ) M-234p and ( H ) M-406 representative images of Control and Cy+Los treated tumors, 1000× magnification.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, TUNEL Assay, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: Hematoxylin and eosin (H&E) representative tumor sections from M-234p and M-406, 400×. In both models the behavior was similar. Control group: ( A ) M-234p and ( C ) M-406: capillaries with small endothelial cells with barely stained nuclei and intercellular gaps (yellow arrow), lack of pericytes or cells with structure and staining compatible with pericytes. Cy+Los group: ( B ) M-234p and ( D ) M-406: intra- and peritumoral capillaries with structure and morphology similar to normal tissues. Endothelial cells with defined nuclei provide a continuous uninterrupted lining (yellow arrow), and well defined basal membrane covered with pericytes (red arrow). M-406 magnified section (1000×): vessel with normal vascular morphology. HIF1α expression: HIF1α + cells/field (median, range). ( E ) Control vs Cy ( P < 0.05), ( F ) Control vs Cy ( P < 0.05), vs Cy+Los ( P < 0.05), ( G ) and H ), representative images of Control and Cy+Los treated tumors, 100× magnification. Kruskal-Wallis multiple comparison test and Dunn’s post-test.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, Staining, Membrane, Expressing, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: M-234p: ( A ) CD4 cells, N. S. ( B ) CD8 cells, N. S. ( C ) Treg cells, N. S. ( D ) Th17 cells, N. S. M-406: ( E ) CD4 cells, N. S. ( F ) CD8 cells, N. S. ( G ) Treg cells, ( P = 0.064). ( H ) Th17 cells: Control vs Cy+Los, ( P = 0.0580). Kruskal-Wallis multiple comparison test and Dunn’s post-test.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: Lymphocytes/field (median, range). M-234p: ( A ) CD4 + cells, N. S. ( B ) CD8 + cells, N. S. ( C ) Foxp3 + cells: Control vs Los, P < 0.05, vs Cy+Los, ( P < 0.05); ( D – F ) representative images of Control and Cy+Los treated tumors, 100× magnification; M-406: ( G ) CD4 + cells, N. S. ( H ) CD8 + cells, N. S. ( I ) Foxp3 + cells: Control vs Cy+Los, ( P < 0.05); ( J – L ) representative images of Control and Cy+Los treated tumors, 100× magnification. Kruskal-Wallis multiple comparison test and Dunn’s post-test.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: Quantification of tumor infiltrating lymphocytes by flow cytometry: M-234p, day 42, Cy vs Cy+Los: ( A ) CD4 cells, N. S. ( B ) CD8 cells, N. S. ( C ) Treg cells, ( P < 0.001). ( D ) Th17 cells, ( P < 0.05). Kruskal-Wallis multiple comparison test and Dunn’s post -test.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Flow Cytometry, Comparison

Journal: Oncotarget

Article Title: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models

doi: 10.18632/oncotarget.27694

Figure Lengend Snippet: αSMA : % of αSMA + area/field (median, range). ( A ) M-234p Control vs Los, ( P < 0.05), vs Cy+Los, ( P < 0.01). ( B ) M-406 Control vs Cy, ( P < 0.01), vs Los ( P < 0.01), vs Cy+Los ( P < 0.001). ( C ) M-234p and ( D ) M-406 representative images of Control and Cy+Los treated tumors, 100× magnification. Kruskal-Wallis multiple comparison test and Dunn’s post-test. Collagen : % of collagen area/field (median, range). ( E ) M-234p Control vs Cy+Los ( P < 0.01). ( F ) M-406 N. S. ( G ) M-234p and ( H ) M-406 representative images of Control and Cy+Los treated tumors, 100× magnification.

Article Snippet: Data obtained was analyzed using ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn’s post-test, and Log-rank tests were used to examine the differences between groups with GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

Techniques: Control, Comparison